MK-7845

Experimental drug

{{Drugbox | verifiedfields = changed | verifiedrevid = 123456789 | IUPAC_name = (2S)-2-[[4-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]pyrimidin-2-yl]amino]butanamide | image = MK-7845.svg | image2 = | width = 200 | alt = | caption = Chemical structure of MK-7845 | tradename = | synonyms = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = DB123456 | ChemSpiderID = 12345678 | UNII = | KEGG = | ChEBI = | ChEMBL = | C=18 | H=18 | F=1 | N=5 | O=1 | S=1 | smiles = | InChI = | InChIKey = }}

MK-7845 is an investigational drug developed by Merck & Co. for the treatment of cardiovascular disease. It is a selective inhibitor of the enzyme acetyl-CoA carboxylase (ACC), which plays a crucial role in fatty acid metabolism.

Mechanism of Action

Chemical structure of MK-7845

MK-7845 functions by inhibiting the activity of acetyl-CoA carboxylase, an enzyme that catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. This reaction is a key step in the biosynthesis of fatty acids. By inhibiting ACC, MK-7845 reduces the production of malonyl-CoA, thereby decreasing fatty acid synthesis and increasing fatty acid oxidation. This mechanism is particularly beneficial in conditions such as non-alcoholic fatty liver disease (NAFLD) and atherosclerosis, where lipid accumulation is a major concern.

Clinical Development

MK-7845 is currently undergoing clinical trials to evaluate its efficacy and safety in patients with cardiovascular diseases. Early-phase studies have shown promising results in reducing triglyceride levels and improving lipid profiles. The drug is also being investigated for its potential benefits in metabolic syndrome and type 2 diabetes mellitus.

Potential Benefits

The inhibition of ACC by MK-7845 offers several potential therapeutic benefits:

• Reduction in Lipid Accumulation: By decreasing fatty acid synthesis, MK-7845 may help reduce lipid accumulation in the liver and other tissues.
• Improvement in Insulin Sensitivity: The drug may improve insulin sensitivity by altering lipid metabolism, which is beneficial for patients with type 2 diabetes.
• Cardiovascular Protection: By improving lipid profiles, MK-7845 may offer protective effects against cardiovascular diseases.

Challenges and Considerations

While MK-7845 shows promise, there are challenges in its development. The long-term effects of ACC inhibition are not fully understood, and there is a need to monitor for potential side effects such as muscle pain or liver toxicity.

Related Pages

• Acetyl-CoA carboxylase
• Fatty acid metabolism
• Cardiovascular disease
• Non-alcoholic fatty liver disease
• Metabolic syndrome